Latest News - Hepatitis B Therapeutics Market 2024-2028: North America Leads Market Growth with Key Trends and Insights

Hepatitis B Therapeutics Market to grow at a CAGR of 3.27% during 2024-2028

The Hepatitis B Therapeutics Market is expected to grow at a CAGR of 3.27% during 2023 and 2028. During this period, the market is also expected to show a growth of USD 469.5 million. The global hepatitis B therapeutics market is witnessing significant growth due to the robust pipeline of innovative treatments and diagnostic solutions. Pharmaceutical companies are leveraging advanced technologies such as CRISPR/Cas9, organ-on-a-chip, nano formulations, liposomal formulations, and pegylated formulations to develop effective therapies. CRISPR/Cas9 technology, in particular, offers a promising approach by specifically targeting open reading frames of the HBV genome, thereby inhibiting viral replication and reducing HBsAg levels. This continuous inhibition of cccDNA expression prevents the virus from multiplying and causing further damage to the liver. 

Get more information on Hepatitis B Therapeutics Market by requesting a sample report

The Drugs subsegment is expected to dominate the Application segment during the forecast period 

Technavio analysts predict that the Drugs subsegment will lead the Application segment during 2024 and 2028 The Hepatitis B Therapeutics Market is experiencing significant growth, particularly in the drugs segment. This expansion is fueled by recent product approvals and cutting-edge technological advancements in hepatitis B treatment. Notably, increased research and development (R&D) expenditures by organizations to develop innovative diagnostic tools and identify the stage of liver infection caused by the virus are driving the demand for targeted pharmaceutical solutions. As a result, the market is poised for continued growth due to the ongoing initiatives and recent approvals of hepatitis B treatment drugs.

Here are the various ways based on which the market is segmented: 

• Application
  • Drugs
  • Vaccines
• Geography
  • North America
    • US
    • Canada
  • Europe
    • France
    • Germany
    • Italy
    • Spain
    • UK
  • APAC
    • Australia
    • China
    • India
    • Japan
    • South Korea
    • Rest of APAC
  • Rest of World (ROW)
    • UAE
    • Saudi Arabia
    • Oman
    • Kuwait
    • Qatar
    • Rest of Middle East and Africa

Key Companies and Market Insights
Some of the key companies in the Hepatitis B Therapeutics Market include:

• Accord Healthcare Inc.
• Apotex Corp.
• Arbutus Biopharma
• Arrowhead Pharma
• Aurobindo Pharma Ltd.
• Bristol-Myers Squibb Co.
• CASI Pharmaceuticals Inc.
• Cipla Inc.
• Dynavax Technologies Corp.
• Emergent BioSolutions Inc.
• F. Hoffmann La Roche Ltd.
• Gilead Sciences Inc.
• GlaxoSmithKline
• Hetero Healthcare Ltd.
• Johnson and Johnson Services Inc.
• Lupin Pharmaceuticals Inc.
• Merck & Co. Inc.
• Novartis AG
• Par Pharmaceutical Inc.
• Sanofi SA

Reasons to Purchase the Global Hepatitis B Therapeutics Market Research Report by Technavio. What is in it for you?

• Wealth of Experience: Technavio is an established name in the world of market research. It holds an expertise of more than 20 years in the field, has published 21,000+ reports thereby extensively covering the area in various industries and range of regions
• Insight into Current Market Trends: Our research reports provide our readers insights into the latest market intelligence, competitor strategies, market trends, changes taking place in the industry and customer preferences, forecasted market opportunities that influence them to make better business decisions
• High ROI with Extensive Hands-on Research: Technavio is renowned for offering personalized market research reports as per unique business needs, delving deep into specific markets, product segments and demographics. Additionally, it is also well-known for providing high return on investments through its wide collection of data at pocket-friendly rates

There are several factors that are causing the market to flourish increasing prevalence of hepatitis b infants

Learn which are the obstacles that the market is experiencing in the way of its growth by accessing the free PDF report

Research Analysis Overview

The Hepatitis B therapeutics market encompasses vaccination services for hepatitis B prevention, as well as drugs used for the treatment of chronic hepatitis B infection. Clinical trials are ongoing for new drugs to address drug resistance and improve treatment outcomes. Hepatitis B and C often co-exist, and the market also includes diagnostics for both viruses. Following a diagnosis, chronic disease management involves regular follow-up, laboratory testing expenses, and healthcare services. Poor sanitation conditions, illicit drugs, and alcohol contribute to the spread of hepatitis B. Biomarker-based testing aids in early detection and monitoring of liver infection caused by the Hepatitis B virus. Recombinant vaccines are available for newborns and infected mothers to prevent prenatal transmission. Chronic infection can lead to complications such as hepatocellular carcinoma, chronic hepatitis, and cirrhosis.

Market Research Overview

The global pharmaceuticals market, encompassing entities involved in the research and development (R&D) or manufacturing of generic and non-generic drugs, as well as veterinary drugs, is a significant sector within the larger healthcare industry. According to Technavio, the healthcare market size is determined by the consolidated revenue generated by providers of equipment, supplies, pharmaceuticals, biotechnology, and life sciences tools and services. Factors driving the expansion of the pharmaceuticals market include the increasing global population aging, with the number of individuals over 60 years old in the US projected to reach approximately 25% by 2050, and Europe projected to reach a similar ratio by 2030.

The Hepatitis B Therapeutics Market is experiencing significant growth, fueled by the increasing prevalence of hepatitis b infants. Industries are leveraging the products belonging to the market for customer engagement, transactional notifications, and promotional offers.

Contacts

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/